Your browser is no longer supported. Please, upgrade your browser.
Settings
MTNB Matinas BioPharma Holdings, Inc. daily Stock Chart
MTNB [AMEX]
Matinas BioPharma Holdings, Inc.
Index- P/E- EPS (ttm)-0.12 Insider Own3.00% Shs Outstand197.60M Perf Week-7.19%
Market Cap168.62M Forward P/E- EPS next Y-0.17 Insider Trans0.00% Shs Float181.84M Perf Month4.93%
Income-21.40M PEG- EPS next Q-0.03 Inst Own26.20% Short Float8.89% Perf Quarter8.01%
Sales0.00M P/S- EPS this Y17.50% Inst Trans-5.39% Short Ratio6.41 Perf Half Y-36.53%
Book/sh0.35 P/B2.36 EPS next Y-41.70% ROA-34.40% Target Price- Perf Year18.07%
Cash/sh0.33 P/C2.48 EPS next 5Y- ROE-41.60% 52W Range0.49 - 2.49 Perf YTD-63.65%
Dividend- P/FCF- EPS past 5Y16.90% ROI- 52W High-66.86% Beta2.94
Dividend %- Quick Ratio28.70 Sales past 5Y- Gross Margin- 52W Low68.39% ATR0.07
Employees21 Current Ratio28.70 Sales Q/Q- Oper. Margin- RSI (14)48.77 Volatility7.80% 9.38%
OptionableNo Debt/Eq0.00 EPS Q/Q-16.20% Profit Margin- Rel Volume0.92 Prev Close0.85
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume2.52M Price0.83
Recom1.80 SMA20-2.49% SMA500.56% SMA200-20.81% Volume2,315,623 Change-2.69%
Jan-27-20Initiated Piper Sandler Overweight $3
Jan-24-20Initiated SunTrust Buy
Jan-23-20Initiated SunTrust Buy
Jan-09-20Initiated Aegis Capital Buy $3.50
Jun-26-19Initiated H.C. Wainwright Buy $4
Aug-10-20 05:35PM  
04:05PM  
Aug-07-20 11:00AM  
Aug-05-20 04:21PM  
Aug-04-20 07:00AM  
Aug-03-20 12:31PM  
Jul-16-20 08:38AM  
Jul-14-20 05:31PM  
Jul-01-20 08:12AM  
Jun-30-20 04:15PM  
Jun-23-20 09:15PM  
Jun-16-20 07:20AM  
May-26-20 07:00AM  
May-19-20 07:35AM  
May-18-20 10:59AM  
May-11-20 07:45PM  
04:05PM  
May-04-20 07:00AM  
Apr-28-20 07:00AM  
Apr-07-20 05:10PM  
Apr-02-20 10:10AM  
Mar-31-20 07:00AM  
Mar-09-20 07:45AM  
06:30AM  
06:00AM  
Mar-08-20 04:14PM  
Mar-05-20 07:00AM  
Mar-04-20 07:00AM  
Feb-24-20 04:15PM  
Feb-19-20 07:00AM  
Feb-12-20 10:08AM  
Jan-31-20 11:14AM  
Jan-21-20 08:41AM  
Jan-14-20 11:21AM  
Jan-10-20 08:00AM  
07:13AM  
Jan-09-20 04:05PM  
Jan-07-20 04:56AM  
Jan-03-20 02:13PM  
Dec-22-19 01:30PM  
Dec-20-19 04:41AM  
Dec-12-19 07:00AM  
Nov-18-19 10:29AM  
07:30AM  
Nov-15-19 08:54AM  
08:25AM  
Nov-13-19 07:45AM  
06:30AM  
Nov-06-19 07:30AM  
Oct-28-19 03:17PM  
Oct-14-19 07:00AM  
Oct-07-19 07:00AM  
Sep-27-19 08:00AM  
Sep-25-19 07:00AM  
Sep-20-19 09:57AM  
Aug-28-19 07:30AM  
Aug-23-19 07:35AM  
Aug-14-19 11:34AM  
Aug-13-19 08:05AM  
06:45AM  
06:30AM  
Aug-06-19 10:30AM  
Jul-30-19 07:30AM  
Jul-25-19 07:30AM  
Jul-09-19 12:13PM  
Jun-03-19 08:05AM  
May-29-19 01:29AM  
May-28-19 08:00AM  
May-22-19 09:29AM  
May-21-19 08:00AM  
May-15-19 07:00AM  
May-14-19 07:00AM  
May-08-19 08:05AM  
May-02-19 08:35AM  
May-01-19 08:35AM  
Apr-11-19 11:07AM  
Apr-02-19 07:05AM  
Mar-26-19 08:00AM  
Mar-18-19 08:35AM  
Mar-15-19 08:45AM  
Mar-14-19 05:02PM  
Feb-25-19 08:05AM  
Jan-16-19 09:00AM  
Jan-10-19 08:00AM  
Jan-03-19 08:20AM  
Dec-20-18 08:35AM  
Dec-19-18 08:35AM  
Dec-06-18 09:00AM  
Nov-26-18 07:55AM  
Nov-23-18 01:48PM  
Nov-13-18 09:15AM  
Nov-12-18 08:45AM  
07:00AM  
Oct-18-18 08:00AM  
Oct-16-18 08:00AM  
Oct-15-18 08:01AM  
Sep-25-18 08:00AM  
Sep-06-18 08:01AM  
Sep-05-18 08:00AM  
Aug-16-18 08:00AM  
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.